Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22473865 | 0.89 | PRMT5 (0.33) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL17229852 | 0.82 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL21385780 | 0.75 | DRD2 (0.34) | PRMT5WDR77PDE10A | |
| SCHEMBL16265181 | 0.72 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL18875749 | 0.72 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL12798307 | 0.71 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL16010651 | 0.71 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL22591291 | 0.69 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL13122629 | 0.68 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL477062 | 0.68 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-9944644-B2 | Octahydropyrrolopyrroles their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | KDM4E 3774/4885ALDH1A1 3010/4885SMN1; SMN2 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.